



University of Copenhagen & Copenhagen University Hospital

Inhibition of PCSK9 synthesis via RNA interference

Børge G Nordestgaard

Professor, Chief Physician, MD, DMSc

Conflict of Interest Disclosure: the Danish tax payer

Consultancies or talks sponsored by AstraZeneca, Omthera, Sanofi, Regeneron, Ionis, Aegerion, Dezima, Fresenius, B Braun, Kaneka, Amgen, Kowa, Denka Seiken

PCSK9 inhibition

Extracellular

Extracellular & intracellular


LDL

LDL-R

PCSK9

Antibodies

RNA interference



Inclisiran

Inhibition of PCSK9 synthesis by RNA interference

50-60% LDL-C↓
over 3-6 months
Injections 2-3x per year


Serious adverse events↑ ?
Liver enzymes↑ ?
Myalgia ?

NonHDL-C↓ less than LDL-C↓
Remnant-C↑ ?
HDL-C↑ Good or bad?
Lp(a)↓ Important?

Side effect
Mild injection-site reaction

Effect

None?



Long-term studies of inclisiran

Inhibition of PCSK9 synthesis by RNA interference

LDL-C ↓ sustainable?

CVD benefit?

Mortality benefit?

Severe injection-site reaction?

Reduction in platelets?

Myalgia - intolerance?

Neurocognitive symptoms?

Off-target effects?

